Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
5.220
-0.130 (-2.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Editas Medicine
< Previous
1
2
Next >
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 2/28
February 28, 2024
Via
Investor Brand Network
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
February 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
February 21, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 9/29
September 29, 2023
Via
Investor Brand Network
Editas Medicine to Participate in Upcoming Investor Conferences
January 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
January 08, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
December 13, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
December 11, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
November 03, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
November 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
October 27, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
October 16, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Editas Medicine Announces Upcoming Investor Events
August 30, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
August 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 27, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
July 26, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
July 24, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Pricing of Offering of Common Stock
June 14, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Offering of Common Stock
June 14, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
June 09, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
June 06, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
May 18, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
May 16, 2023
Michelle Robertson to remain with Company until August 16, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
May 11, 2023
Company-sponsored webinar to be announced
From
Editas Medicine, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.